Evelyn Partners Investment Management LLP Decreases Position in Johnson & Johnson $JNJ
Evelyn Partners Investment Management LLP reduced its stake in Johnson & Johnson by 11% in Q2, owning 112,275 shares worth $18.93 million. Other investors adjusted their positions, with Brighton Jones LLC increasing its stake by 13.9%. EVP Jennifer L. Taubert sold 56,471 shares, decreasing her ownership by 24.08%. JNJ stock opened at $203.88, with a market cap of $491.21 billion. Analysts predict a 10.58 EPS for the year and set new price targets, including a $230 objective by Scotiabank.
Evelyn Partners Investment Management LLP decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 112,275 shares of the company's stock after selling 13,850 shares during the period. Johnson & Johnson comprises approximately 0.9% of Evelyn Partners Investment Management LLP's portfolio, making the stock its 27th biggest holding. Evelyn Partners Investment Management LLP's holdings in Johnson & Johnson were worth $18,932,000 at the end of the most recent quarter.
- Why GRAIL Stock Could Be Biotech’s Next Big Breakout
Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new stake in Johnson & Johnson in the 1st quarter valued at approximately $218,000. Smart Money Group LLC grew its holdings in Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company's stock valued at $1,109,000 after buying an additional 407 shares during the last quarter. United Bank increased its position in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after buying an additional 4,876 shares in the last quarter. Finally, Noesis Capital Mangement Corp raised its holdings in shares of Johnson & Johnson by 12.0% in the first quarter. Noesis Capital Mangement Corp now owns 9,031 shares of the company's stock worth $1,498,000 after acquiring an additional 971 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Get Johnson & Johnson alerts:
Insider Activity
In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.
Johnson & Johnson Stock Up 0.4%
- 3 Smart Defensive Stocks for an Uneasy Market
JNJ stock opened at $203.88 on Friday. The firm has a market cap of $491.21 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $206.94. The firm has a fifty day moving average price of $188.25 and a two-hundred day moving average price of $171.55. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Dividend Announcement
- Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is presently 50.19%.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Scotiabank initiated coverage on Johnson & Johnson in a research note on Thursday, November 13th. They set a "sector outperform" rating and a $230.00 price objective on the stock. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a report on Monday, October 6th. Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Finally, Cowen restated a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $201.05.
Read Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Profile
(Free Report)Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- Best Aerospace Stocks Investing
- MarketBeat Week in Review – 11/17 - 11/21
- Upcoming IPO Stock Lockup Period, Explained
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- What Are Dividend Champions? How to Invest in the Champions
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Johnson & Johnson Right Now?
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
